Macular Thickness Decrease in Asymptomatic Subjects at High Genetic Risk of Developing Alzheimer’s Disease: An OCT Study

Inés López-Cuenca 1,3, Rosa de Hoz 1,2,3, Elena Salobrar-García 1,2,3, Lorena Elvira-Hurtado 1, Pilar Rojas 1,4, José A. Fernández-Albarral 1, Ana Barabash 5,6, Juan J. Salazar 1,2,3, Ana I. Ramírez 1,2,3,* and José M. Ramírez 1,2,8

1 Instituto de Investigaciones Oftálmologicas Ramón Castroviejo, Universidad Complutense de Madrid (UCM), 28040 Madrid, Spain; inelopez@ucm.es (I.L.-C.); rdehoz@med.ucm.es (R.d.H.); elenasalobrar@med.ucm.es (E.S.-G.); marelVir@ucm.es (L.E.-H.); pilar.rojas.lozano@gmail.com (P.R.); joseaf08@ucm.es (J.A.F.-A.); jjsalazar@med.ucm.es (J.J.S.)

2 OFTARED-ISCIII, IIORC (UCM), 28011 Madrid, Spain

3 Departamento de Inmunología, Oftalmología y ORL, Facultad de Óptica y Optometría, UCM, 28037 Madrid, Spain

4 Hospital General Universitario Gregorio Marañón, Instituto Oftálmico de Madrid, 28007 Madrid, Spain

5 Endocrinology and Nutrition Department, Hospital Clínico Universitario San Carlos and Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, 28040 Madrid, Spain; ana.barabash@gmail.com

6 Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, 28029 Madrid, Spain

7 Departamento de Inmunología, Oftalmología y ORL, Facultad de Medicina, UCM, 28040 Madrid, Spain

* Correspondence: airamirez@med.ucm.es (A.I.R.); ramirezaz@med.ucm.es (J.M.R.)

† These authors (I.L.-C. and R.d.H.) contributed equally to this work.

Received: 2 May 2020; Accepted: 1 June 2020; Published: 3 June 2020

Abstract: In this case control study, we examined the retinal thickness of the different layers in the macular region and peripapillary retinal nerve fiber layer (RNFL) with optical coherence tomography (OCT) in healthy cognitive subjects (from 51 to 74 years old) at high genetic risk for developing Alzheimer’s disease (AD). Thirty-five subjects with a family history of Alzheimer disease (AD) (FH+) and ApoE ε4 carriers and 29 age-matched control subjects without a family history of AD (FH−) and ApoE ε4 non-carriers were included. Compared to FH− ApoE ε4 non-carriers, in FH+ ApoE ε4 carriers, there were statistically significant decreases (p < 0.05) in (i) the foveal area of mRNFL; (ii) the inferior and nasal sectors in the outer and inner macular ring in the inner plexiform layer (IPL); (iii) the foveal area and the inferior sector in the outer macular ring in the inner nuclear layer (INL); and (iv) the inferior sector of the outer macular ring in the outer plexiform layer (OPL). However, no statistically significant differences were found in the peripapillary thickness of RNFL between both study groups. In subjects with cognitive health and high genetic risk for the development of AD, initial changes appeared in the macular area. OCT could be a promising, cost-effective and non-invasive test useful in early AD, before the onset of clinical symptoms.

Keywords: Alzheimer’s disease; ApoE ε4; first-degree family history; genetic risk; OCT; retina

1. Introduction

One of the main genetic risk factors for developing sporadic Alzheimer’s Disease (AD) is having a first-degree family history of the disease [1], another major genetic risk factor is mediated by ApoE...
This gene has been implicated in modulating the metabolism and aggregation of Aβ [3]. There are three alleles of APOE, ε2, ε3 and ε4, and they encode for apolipoprotein E (ApoE) [4]. ApoE4 increases the risk of AD by three times per ε4 allele, with the risk being highest among people of European descent [5]. Moreover, the mean age at the clinical onset of AD has been estimated at 68 years for ε4 homozygotes and 76 years for ε4 heterozygotes[6]. Although genetics is not included in the research framework because the gene variants do not measure pathological changes or indicate any particular stage of AD [7], ApoE ε4 has been reported to affect magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) and cognitive biomarkers [8], and it may have intrinsic effects on brain function [9]. In addition, ApoE ε4 plus high levels of amyloid beta (Aβ) proteins are associated with episodic memory decline and high risk for clinical AD [10], and ApoE ε4 carriers are also more vulnerable to environmental factors [11].

For years, changes in subjects at high risk of developing AD have been studied [12–16]. Casual findings such as the presence of white matter hyper-intensities, vascular abnormalities and the loss of brain volume have been reported in some MRI studies [12,17]. In magnetoencephalographic (MEG) studies, the functional connectivity of cognitively healthy subjects at high risk of AD showed areas where this connectivity decreased and others where it improved. In these areas between the precuneus and the bilateral inferior parietal lobes, in which there is more activity, they have a neuronal hyper-synchronization that can be explained as an early abnormal excitatory response by the effect of Aβ accumulation [18]. Previously, it has been reported that neurons near amyloid plaques become hyperactive [19], showing a decrease in synaptic inhibition as a possible cause of hyperactivity. It is known that signs of dementia can appear decades before clinically detectable symptoms [20,21]. For all these reasons, interest in finding new biomarkers of the disease has focused on earlier stages of AD [22], searching for less invasive methods and easily accessible tissues such as the retina [23,24].

There is a clear link between retinal and cerebral changes in AD [23]. In preclinical and prodromal stages, retinal changes have also been reported in the optical coherence tomography (OCT) [25,26], as well as the existence of associations between quadrant-specific retinal nerve fiber layer (RNFL) thickness and the brain regions analyzed by 3T MRI [27].

The aim of this work was to analyze by OCT the existence of possible structural changes in the retina, both in the macular and in the peripapillary area, in subjects with two marked genetic risk factors for AD: first-degree family history of AD and being carrier of at least one ε4 allele for the ApoE gene.

2. Materials and Methods

2.1. Study Design

“The cognitive and neurophysiological characteristics of subjects at high risk of developing dementia: a multidimensional approach” (COGDEM study) was conducted in different centers including the Centre for Biomedical Technology (CBT), the San Carlos Clinical Hospital in Madrid (HCSC), the Ramon Castroviejo Institute of Ophthalmic Research (IIORC) in the Complutense University of Madrid (UCM), Spain. All the study participants provided written informed consent. The research followed the tenets of the Declaration of Helsinki, and the study was approved by the local Ethics Committee (HCSC) with the internal code 18/422-E_BS.

We analyzed two groups: subjects with a family history of AD (FH+) and their respective controls. The group (FH+) was made up of middle-aged subjects with at least one parent with sporadic AD. Their clinical records should not show a history of neurological or psychiatric disorders or suffering from a serious medical condition. To verify the parent’s diagnosis of AD, a multidisciplinary diagnostic consensus panel reviewed the parent’s medical records. Experts at the HCSC reviewed the diagnostic procedures to select only those diagnoses that were made under internationally accepted criteria. Although autopsy reports verified by a pathologist were welcome, this may not be an inclusion criterion since this procedure was not performed in most AD patients. Families with known autosomal dominant mutations (i.e., presenilin-1 or 2) were not included. As
controls for the FH+ group, we selected middle-aged subjects in whom the absence of a first-degree family history of AD (FH−) was determined through the participant's self-report in response to a detailed medical history questionnaire. This FH− group was matched with the FH+ group in terms of age, socioeconomic status and other demographic characteristics. In addition, no previous history of neurological or psychiatric disorder or any serious medical condition was an inclusion criterion for this sample. Both the FH+ and FH− groups showed normal scores (above 26) on the Mini Mental State Examination (MMSE). They also showed normal MRI with no evidence of brain lesion or pathology.

Because approximately 15% of the general population carries ApoE ε4, we decided to include this genetic factor as a covariate in our study. For the analysis of ApoE genotyping, DNA was extracted from 10 mL blood samples in ethylenediaminetetraacetic acid from the FH+ and FH− subjects. ApoE was detected using TaqMan assay technology on an Applied Biosystems 7500 Fast Real-Time PCR machine (Applied Biosystems, Foster City, CA, USA). ApoE alleles were determined by analyzing two single-nucleotide polymorphisms (SNPs), rs7412 and rs429358 genotypes, with TaqMan Genotyping Assays (C\textsubscript{904973}_10 and C\textsubscript{3084793}_20, respectively).

2.2. Subjects

We reviewed the COGDEM study database, which consists of 251 patients. In our study, none of the subjects could have an ophthalmological pathology that could modify the measures by OCT, and for this reason we performed a phone screening with all the patients to assess their ophthalmological history. The questions are shown in Table 1. Forty-four subjects refused to participate, and seventeen had ocular pathology.

| Table 1. Telephone screening questions. |
|----------------------------------------|
| Do you use glasses? Yes/No              |
| Do you know if you have myopia, hypermetropia or astigmatism? |
| Do you know how much diopters?          |
| Do you have any ocular pathology? Yes/No |
| Do you have any type of ocular treatment? Yes/No |
| Do you have any type of ocular surgery performed? Yes/No |

2.3. Ophthalmological Tests

All remaining participants (n = 190) were examined in the clinic of the Ramon Castroviejo Institute of Ophthalmic Research, where an eye examination was performed. For the study, one eye of each patient was randomly selected. The visual exam included visual acuity, slit-lamp examination, applanation tonometry (Perkins MKII tonometer, Clement Clarke International, Essex, England), a dilated fundus and an OCT examination (Heidelberg Engineering, Heidelberg, Germany).

In addition to the general inclusion criteria, all the participants met the ophthalmological inclusion criteria listed in Table 2.

Of these 190 subjects, after the ophthalmological examination, we excluded 60 participants for different ophthalmologic pathologies or conditions that were unknown for them. Finally, the remaining 130 patients were divided into 57 FH+ ApoE ε4 non-carriers, 35 FH+ ApoE ε4 carriers, 29 FH− ApoE ε4 non-carriers and 9 FH− ApoE ε4 carriers. Since in our study we considered being an ApoE ε4 carrier as inclusion criteria, 35 FH+ ApoE ε4 carriers and 29 FH− ApoE ε4 non-carriers (control group) participated, being a total of 64 adults aged between 51 and 74 years (Figure 1).

| Table 2. Ophthalmological inclusion criteria. |
|-----------------------------------------------|
| Being free of ocular disease or posterior pole pathology |
| Macular degeneration                          |
| Drusen                                        |
| Glaucoma or suspicion                         |
Figure 1. Flow diagram of patient’s inclusion. (COGDEM): “The cognitive and neurophysiological characteristics of subjects at high risk of developing dementia: a multidimensional approach”; (FH+), subjects with a family history of Alzheimer’s disease (AD); (FH−) subjects without a family history of AD. In greyscale, patients who participated in the ophthalmological study and were included in our study.

2.4. Optical Coherence Tomography

OCT images were captured with Spectralis OCT (Heidelberg Engineering, Heidelberg, Germany). Spectralis Glaucoma Module Premium Edition was used, which offers an anatomic positioning system (APS) based on two fixed points: the center of the fovea and the center of Bruch’s membrane opening (BMO). At the optic nerve head (ONH), a 4-line high-resolution radial scan and three-circle scans, both centered on BMO, were acquired to provide highly reproducible RNFL thickness results. In the macular area, which was centered on the APS of Glaucoma Module Premium, 121 dense B-scans were performed per eye.

The total thickness of the retina and the thickness of each retinal layer in the macular area were measured with Heidelberg segmentation software (Heidelberg, Germany, version 1.10.4.0). This segmentation was checked by the same optometrist (IL-C) and modified manually if required. The thicknesses of the following layers of the retina were analyzed: retinal nerve fiber layer (RNFL), ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL) and retinal pigment epithelium (RPE) (Figure 2C). The inner and outer macular rings were analyzed according to the standard Early Treatment Diabetic Retinopathy Study (ETDRS) macular grid (a foveal area of 1 mm of diameter, 1–3 mm around the fovea in the inner ring and 3–6 m for the outer ring) [28] (Figure 2A). Peripapillary RNFL (pRNFL) thickness was measured in six sectors (nasal, supero-nasal, infero- nasal, temporal, supero-temporal, infero-temporal), also obtaining an average over all sectors (Global) (Figure 2B). Good-quality scans were considered with a signal-to-noise ratio >30 and 95% accepted A-Scans. According to the calibration provided by the manufacturers, the measurements were given in microns. Both eyes of each subject were scanned, but only one eye of each participant was used in this study. The scans were obtained after pharmacological mydriasis at under room light conditions.
Figure 2. Optical coherence tomography (OCT) report of the retinal thickness analysis. (A) Concentric macular rings. (B) Peripapillary sectors. (C) Macular thickness segmentation of all retinal layers. (ST: supero-temporal; SN: supero-nasal; N: nasal; IN: infero-nasa; IT: infero-temporal; T: temporal and G: global).

2.5. Statistical analysis

Statistical analysis was carried out in SPSS 25.0 (SPSS Inc., Inc., Chicago, IL, USA). The distribution of the sample was analyzed using visual methods including histograms, Q-Q plot graphics as well as Kolmogorov–Smirnov and Shapiro–Wilk normality tests.

Data are reported as the median (interquartile range). The differences between the study groups (FH+ ApoE ε4 carriers and FH− ApoE ε4 non-carriers) were analyzed using a Mann–Whitney U Test. For the analysis of qualitative variables, a chi-squared test was used. A p value ≤0.05 was considered statistically significant.

3. Results

Demographic data for FH+ ApoE ε4 carriers and FH− ApoE ε4 non-carriers are shown in Table 3.

Table 3. Demographic data of the study population.

|                      | FH+ ApoE ε4 Carriers | FH− ApoE ε4 Non-Carriers | P-value |
|----------------------|----------------------|--------------------------|---------|
| Number of participants (n) | 35                   | 29                       |         |
| Age (years)          | 57.00 (54.00–61.00)  | 59.00 (54.00–65.00)      | 0.164   |
| Sex                  |                      |                          |         |
| Male/Female          | 11/24                | 12/17                    | 0.028 */0.353 1 |
| MMSE                 | 29.00 (29.00–29.00)  | 29.00 (28.00–29.00)      |         |

Median (interquartile range); *P < 0.05. Mann–Whitney U and chi-square tests; 1P-value of different sex in the same group; SD: standard deviation; FH+: subjects with a family history of AD; FH−: subjects without a family history of AD. MMSE: Mini Mental State Examination.
There were statistically significant differences ($p < 0.05$) between the sex of the subjects in the group of FH+ ApoE ε4 carriers (11 males/24 females), while in the control group there were no significant differences. Regarding the mean age of the participants, there was no significant difference between FH+ ApoE ε4 carriers (57.00 (54.00–61.00)) and FH− ApoE ε4 non-carriers (59.00 (54.00–65.00)). The mean MMSE scores were (29.00 (29.00–29.00)) in the FH+ ApoE ε4 carrier group and (29.00 (28.00–29.00)) in the FH− ApoE ε4 non-carrier group.

3.1. Macular Thickness Analysis by OCT

Regarding the total retinal thickness, there were no significant differences between the study groups in any of the sectors analyzed ($p > 0.05$), with the foveal sector being the thinnest in the eyes of FH+ ApoE ε4 carriers in comparison to eyes of FH− ApoE ε4 non-carriers (Figure 3).

The thickness of the macular retinal nerve fiber layer (mRNFL) showed a significant thinning ($p < 0.05$) in the foveal area in the group of FH+ ApoE ε4 carriers (12.00 (10.00–13.00)) compared to that of the group of FH− ApoE ε4 non-carriers (13.00 (11.50–14.00)). (Figure 3).

In comparison to the FH− ApoE ε4 non-carrier group, FH+ ApoE ε4 carriers showed a non-significant, slight reduction of all the sectors in the thickness of GCL (Figure 3).

In the IPL of FH+ ApoE ε4 carriers, the inferior sectors, both in the inner macular ring (41.00 (39.00–42.00)) and outer macular ring (27.00 (25.00–29.00)), were statistically reduced ($P < 0.05$ in both cases) with respect to the FH− ApoE ε4 non-carrier group. This significant thinning ($P < 0.05$) was also observed in the inner (42.00 (40.00–44.00)) and outer (30.00 (27.00–31.00)) macular rings in the nasal sector. (Figure 3).

In the INL, the FH+ ApoE ε4 carriers, with respect to the FH− ApoE ε4 non-carrier group, showed a significant thickness decrease in the outer macular ring in the inferior sector (31.00 (29.00–32.00)) and in the foveal sector (18.00 (16.00–21.25)) ($P < 0.05$ in both cases) (Figure 3).

![Figure 3. Colorimetric differences in the retinal thickness in each layer between the groups. FH+ ApoE ε4 carriers vs. FH− ApoE ε4 no-carriers in the macular OCT rings. In red, thickening; in blue, thinning. (RNFL: retinal nerve fiber layer; GCL: ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear layer; OPL: outer plexiform layer; ONL: outer nuclear layer; RPE: retinal pigment epithelium). *$P < 0.05$. Mann–Whitney U test.](image)

In the OPL of the FH+ ApoE ε4 carriers, a significant decrease ($p < 0.05$) in the outer macular ring in the inferior sector (27.00 (26.00–29.00)) was observed compared to the group of FH− ApoE ε4 non-carriers (30.00 (27.00–32.50)). (Figure 3).
In the analysis of ONL, no significant difference was observed between the two study groups. However, in FH+ ApoE e4 carriers, with respect to FH– ApoE e4 non-carriers, a slight increase in the thickness of the outer macular ring was observed in all sectors, as well as in the nasal and inferior sectors of the inner macular ring (Figure 3).

Regarding the thickness of the RPE, there were no statistically significant differences between the two study groups in any of the analyzed sectors (Figure 3).

3.2. Peripapillary RNFL Segmentation Thickness Analysis by OCT

In the pRNFL, the comparison between the FH+ ApoE e4 carriers with respect to the FH– ApoE e4 non-carriers showed no statistically significant thickness differences in any of the sectors analyzed. However, in the FH+ ApoE e4 carrier group, while a slight decrease was found in the superior nasal, inferior temporal and temporal sectors, a slight increase was observed in the nasal and nasal inferior sectors with respect to the FH– ApoE e4 non-carrier group (Figure 4).

![Figure 4. Colorimetric differences in the peripapillary RNFL thickness between the groups. FH+ ApoE e4 carriers vs. FH– ApoE e4 non-carriers in the peripapillary OCT sectors. In red, thickening; in blue, thinning, (ST: supero-temporal; SN: supero-nasal; N: nasal; IN: infero-nasal; IT: infero-temporal; T: temporal and G: global). Non-statistical differences were observed.]

4. Discussion

To our knowledge, few studies have analyzed retinal thickness in healthy cognitive subjects at high genetic risk of developing Alzheimer’s dementia [25,26,29–31]. One of the highlights of this study was the careful selection of cases. All participants were free of ocular pathology and cognitive, psychological and behavioral disorders that could mask the results. Only family members of people diagnosed with AD were selected for this study.

In our study, in the FH+ ApoE e4 carrier group there was a statistically significant difference between the sex of the participants (11 men / 24 women). This difference could be explained by women being more likely to develop dementia, so they may be more interested in participating in the study [32]. In addition, women have traditionally been the caregivers because they may feel the losses associated with mental disorders in their families more acutely than men [33]. They commonly participate in studies for two reasons: advances in AD research that will benefit family, friends, or future generations and personal concerns about memory [34].

The association between pRNFL thickness measurements and brain structure volumes in nondemented older adults is now well known [27,35]. There are direct correlations between RNFL thickness in the temporal quadrant with medial temporal lobe volume and especially with the hippocampus volume [27]. Moreover, the inferior quadrant was associated with lingual gyrus
volume. These changes, which were reported in previous studies, suggested that changes in the RNFL thickness could be used as an early marker of AD-related brain atrophy [27,36]. In addition, a decrease in pRNFL thickness has been correlated with impaired cognition during disease progression [37–40]. This pRNFL decrease was confirmed as a potential biomarker for predicting cognitive decline in older adults during preclinical dementia [36]. The association between the atrophy of brain areas and changes in retinal thickness means that the retina may be a potential biomarker for neurodegenerative diseases, as it is non-invasive, it is cost-effective and it is promising in the early stages of AD and even in subjects at high risk of developing dementia.

As far as we know, this is the first study that analyzed by OCT, both in macular and peripapillary regions, all the layers of the retina in cognitively healthy subjects at high risk of developing Alzheimer’s dementia due to two risk factors: having a family history and being a carrier of ApoE ε4. OCT was able to detect very early thickness changes in the macular region, which were very small (±7 μm) in comparison to thickness changes observed in diagnosed AD patients.

In our study, in the analysis of the mRNFL, we found a significant thinning in the foveal sector in the group of FH+ ApoE ε4 carriers compared to the FH− ApoE ε4 non-carrier group. It is surprising to find changes in retinal thickness among these study groups since it must be remembered that FH+ ApoE ε4 carriers are cognitively healthy subjects.

In preclinical studies of AD there are some differences. Some authors did not find significant differences through RNFL analysis in the total macular volume thickness between the AD preclinical group and the control group [29]. More recently, a significant decrease in the total macular volume has been described in preclinical AD with respect to the control groups. These changes appeared after a 27 month follow-up and were related to the neocortical accumulation of Aβ [26]. However, in another study, no significant differences were found between participants with Aβ deposits in the inner layers of the retina in the macular region and those without Aβ deposits in these layers [25]. In these three works, the preclinical groups were made up of people who had a family member with AD but also had subjective memory complaints. They were possibly in the pre-dementia stage with mild cognitive impairment (MCI), which the authors call the preclinical stage. In this stage, the pathology is present in the memory system of the medial temporal lobe, and the neurofibrillary pathology has already begun [26]. Aβ deposits could also be found in mRNFL, compensating in part for the decrease in mRNFL thickness seen in our FH+ ApoE ε4 carriers. Therefore, the reduction in mRNFL thickness could be observed before the damage to the mesiotemporal central nervous memory system, which is characteristic of early AD [26]. For this reason, we suggest that the loss of mRNFL thickness could be a feature of early AD or in subjects at high risk of developing AD.

In patients with established AD, a reduction in mRNFL thickness has been demonstrated in different sectors [37,41–43]. The difference between the inclusion criteria of these patients, in relation to the MMSE, makes the classification of the different stages of AD not equivalent. Possibly, for this reason, the results obtained by different authors were not the same. The greatest thinning was observed in the outer macular ring, in the superior and inferior sectors. This predominant alteration could be explained by the greater concentration of axonal bundles that were directed towards the optic nerve head in these sectors [23].

Few studies have analyzed the thickness of mRNFL in patients with MCI [36,44]. While some studies reported a reduction in the macular volume in MCI patients with respect to controls [36], others found increased macular volumes in MCI patients [44]. The increase of macular volume in MCI could be attributed to gliosis prior to neuronal loss and the atrophy of mRNFL [45].

In our study, the thickness of GCL in FH+ ApoE ε4 carriers showed a slight but not significant reduction in all the sectors with respect to controls. Most of the studies that analyzed this layer in preclinical AD groups also found no significant difference with respect to the control groups [25,26,29,30]. However, the decreased GCL thickness was the main cause of retinal thinning in patients diagnosed with AD [41]. This GCL thinning has been found both in mild AD patients [37] and mild-to-moderate AD patients [46]. In MCI, this thickness decrease has also been suggested as a possible tool to detect neuronal injury [47].
We found that the inferior and nasal sectors, both in the inner and outer macular rings of the IPL, showed significant thinning in the group of FH+ ApoE ε4 carriers compared to that of FH− ApoE ε4 non-carriers, with the IPL retinal layer showing more sectors with statistically significant thickness decreases. In a previous study, in subjects with subjective memory complaints, authors also found a significant thickness reduction in the inferior quadrant [26]. However, the results were different in patients with Aβ+ who showed an increase in the volume of this layer [30]. The thickness decrease found in our FH+ ApoE ε4 carrier subjects in IPL could be explained by the decreased cholinergic activity in this layer, as already described in histopathological studies of asymptomatic patients with the presence of Aβ deposits [48,49]. In more advanced stages of dementia (MCI and established AD), the GCL and the IPL have been analyzed as a complex, showing a thickness decrease in all the quadrants with respect to the control groups [41,47].

At INL, we found a significant thickness decrease in the foveal sector and in the inferior sector of the outer macular ring in our FH+ ApoE ε4 carriers. Only one previous study analyzed the thickness of all the retinal layers in the preclinical stage of AD, although they found no differences in the INL compared to the control group [26]. The absence of changes in this layer could be because this sample presented subjective memory complaints, as they were in a more advanced stage than our healthy cognitive subjects at high risk of developing dementia.

Regarding the outer layers of the retina, the inferior sector in the outer macular ring of the OPL was the only one with significant thinning. In addition, we found that the same sectors that showed a non-significant slight thickness decrease in the OPL (nasal and inferior) also showed a slight, non-significant increase in the ONL. In a previous study where we conducted a spatial analysis of thickness changes in the retinal layers of AD patients measured by OCT, we found that the use of concentric rings could detect the thickening and thinning of neighboring layers within the same region [50]. For this reason, the thickness changes of adjacent layers can be compensated for [50]. In addition, only in preclinical subjects who reported subjective memory complaints were significant changes in ONL thickness detected, with respect to the control group, which were explained as a possible consequence of retrograde transynaptic degeneration [26].

Regarding RPE thickness, there were no statistically significant differences between any of the study groups in any of the sectors analyzed. No previous studies have analyzed this layer in preclinical patients. We found no significant changes in patients with established AD [37,51].

As expected, in the present work we did not find significant changes in any of the peripapillary sectors of RNFL. However, in patients with moderate AD we found a statistically significant thickness decrease in comparison to the control group. Changes in this peripapillary area have been associated with disease progression and the advance of cognitive decline, determined by the MMSE score [37].

Although we found an association between reduced retinal thickness in specific areas and the risk of developing AD dementia, a limitation of this study is that no data are available on how this thinning of the retina correlates with brain or retinal markers of AD. Although a family history of AD and an ApoE genotype ε4 increases the risk of developing AD dementia, not all of our patients at high risk of developing AD will develop the disease. Therefore, the high-risk group in this study possibly included both people who will develop AD dementia and some who will not. This could limit the ability of retinal thickness measurements in patients at high risk of developing AD to be used as an early biomarker. In addition, the same subjects would need to be analyzed over time to evaluate how many of them will develop the disease in the future. The subjects included in our study belonged to a multidimensional study (COGDEM) which will conduct their follow-up.

In conclusion, in cognitively healthy subjects who are asymptomatic but at high genetic risk of developing Alzheimer’s-type dementia, OCT is able to detect very early thickness changes in the macular region, which are very slight (around ±7 μ). These changes showed statistically significant decreases in (i) the foveal area of the mRNFL; (ii) the inferior and nasal sectors in the outer and inner macular ring in the IPL; (iii) the foveal area and the inferior sector in the outer macular ring in the INL; and (iv) the inferior sector of the outer macular ring in the OPL. Therefore, OCT could be a useful tool for diagnosing, monitoring and screening patients at high genetic risk of developing AD,
and it is a promising, cost-effective, non-invasive test useful for the early stages of the disease, before the onset of clinical symptoms.

**Author Contributions:** Conceptualization, I.L.-C., R.dH., E.S.-G., J.J.S., A.I.R., AB and J.M.R.; data curation, I.L.-C., E.S.-G., I.E.-H, AB and J.A.F.-H.; formal analysis, I.L.-C., R.dH., E.S.-G., I.E.-H., P.R. and J.A.F.-A.; funding acquisition, J.J.S., A.I.R. and J.M.R.; investigation, I.L.-C., R.dH., E.S.-G., I.E.-H., P.R., J.A.F.-A and J.M.R.; methodology, I.L.-C., E.S.-G., I.E.-H, P.R, AB and A.I.R.; project administration, J.J.S., A.I.R. and J.M.R.; resources, R.dH.; supervision, R.dH., J.J.S. and J.M.R.; validation, I.L.-C., E.S.-G., AB J.J.S., A.I.R. and J.M.R.; visualization, I.L.-C., R.dH., E.S.-G., I.E.-H., P.R., J.A.F.-A., J.J.S., A.I.R. and J.M.R.; writing—original draft, I.L.-C., R.dH., E.S.-G., P.R., J.A.F.-A., A.I.R. and J.M.R.; writing—review and editing, I.L.-C., R.dH., E.S.-G., J.A.F.-A., J.J.S., A.I.R. and J.M.R. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Ophthalmological Network OPTARED (RD16/0008/0005) of the Institute of Health of Carlos III of the Spanish Ministry of Science and Innovation; and the Research Network RETIBRAIN (RED2018-102499-T) of the Spanish Ministry of Science and Innovation; and Grant PSI2015-68793-C3-1-R of the Spanish Ministry of Economy and Competitiveness. I.L.-C is currently supported by a Predoctoral Fellowship (CT42/18-CT43/18) from the Complutense University of Madrid. J.A.F.-A. is currently supported by a Predoctoral Fellowship (FPU17/01023) from the Spanish Ministry of Science, Innovation, and Universities. The sponsor or funding organization had no role in the design or conduct of this research.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Donix, M.; Small, G.W.; Bookheimer, S.Y. Family history and APOE-4 genetic risk in Alzheimer’s disease. *Neuropsychol. Rev.* 2012, 22, 298–309, doi:10.1007/s11065-012-9193-2.

2. Shaw, L.M.; Arias, J.; Blennow, K.; Galasko, D.; Molinuevo, J.L.; Salloway, S.P.; Schindler, S.; Carrillo, M.C.; Hendrix, J.A.; Ross, A.; et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease. *Alzheimer’s Dement.* 2018, 14, 1505–1521, doi:10.1016/j.jalz.2018.07.220.

3. Poirier, J.; Bertrand, P.; Kogan, S.; Gauthier, S.; Davignon, J.; Bouthillier, D. Apolipoprotein E polymorphism and Alzheimer’s disease. *Lancet* 1993, 342, 697–699, doi:10.1016/0140-6736(93)91705-q.

4. Budelier, M.M.; Bateman, R.J. Biomarkers of Alzheimer Disease. *J. Appl. Lab. Med.* 2019, 5, 194–208.

5. Corbo, R.M.; Scacchi, R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE4 a ‘thifty’ allele? *Ann. Hum. Genet.* 1999, 63, 301–310, doi:10.1046/j.1469-1809.1999.6340301.x.

6. Corder, E.; Saunders, A.; Strittmatter, W.; Schmechel, D.; Gaskell, P.; Small, G.; Roses, A.; Haines, J.; Pericak-Vance, M. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. *Science* 1993, 261, 921–923, doi:10.1126/science.8346443.

7. Jack, C.R.; Bennett, D.A.; Blennow, K.; Carrillo, M.C.; Dunn, B.; Haeberlein, S.B.; Holtzman, D.M.; Jagust, W.; Jessen, F.; Karlawish, J.; et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. *Alzheimer’s Dement.* 2018, 14, 535–562, doi:10.1016/j.jalz.2018.02.018.

8. Leoni, V. The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer’s disease. *Clin. Chem. Lab. Med.* 2011, 49, 375–383, doi:10.1515/cclm.2011.088.

9. Trachtenberg, A.J.; Filippini, N.; Ebmeier, K.P.; Smith, S.M.; Karpe, F.; Mackay, C. The effects of APOE on the functional architecture of the resting brain. *NeuroImage* 2012, 59, 565–572, doi:10.1016/j.neuroimage.2011.07.059.

10. Lim, Y.Y.; Villemagne, V.L.; Pietrzak, R.H.; Ames, D.; Ellis, K.; Harrington, K.; Snyder, P.J.; Martins, R.N.; Masters, C.L.; Rowe, C.C.; et al. APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer’s disease. *Neurobiol. Aging* 2015, 36, 1239–1244, doi:10.1016/j.neurobiolaging.2014.12.008.

11. Kivipelto, M.; Rovio, S.; Ngandu, T.; Käreholt, I.; Eskelinen, M.; Winblad, B.; Hachinski, V.; Cedazo-Minguez, A.; Soininen, H.; Tuomilehto, J.; et al. Apolipoprotein E ε4 magnifies lifestyle risks for dementia: A population-based study. *J. Cell. Mol. Med.* 2008, 12, 2762–2771.

12. Bookheimer, S.Y.; Strojwas, M.H.; Cohen, M.S.; Saunders, A.M.; Pericak-Vance, M.A.; Mazziotta, J.C.; Small, G.W. Patterns of brain activation in people at risk for Alzheimer’s disease. *N. Engl. J. Med.* 2000, 343, 450–456, doi:10.1056/NEJM2000081734340701.
13. Reiman, E.M.; Uecker, A.; Caselli, R.J.; Lewis, S.; Bandy, D.; De Leon, M.; De Santi, S.; Convit, A.; Osborne, D.; Weaver, A.; et al. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer’s disease. *Ann. Neurol.* **1998**, *44*, 288–291, doi:10.1002/ana.410440226.

14. Bendlin, B.B.; Ries, M.L.; Canu, E.; Sodhi, A.; Lazar, M.; Alexander, A.L.; Carlsson, C.M.; Sager, M.A.; Asthana, S.; Johnson, S.C. White matter is altered with parental family history of Alzheimer’s disease. *Alzheimer’s Dement.* **2010**, *6*, 394–403, doi:10.1016/j.jalz.2009.11.003.

15. Badia, M.-C.; Giraldo, E.; Dasi, F.; Alonso, D.; Lainez, J.M.; Lloret, A.; Viña, J. Reductive stress in young healthy individuals at risk of Alzheimer disease. *Free Radic. Biol. Med.* **2013**, *63*, 274–279, doi:10.1016/j.freeradbiomed.2013.05.003.

16. Badia, M.-C.; Giraldo, E.; Dasi, F.; Olaso, G.; Alonso, M.-D.; Viña, J. Lymphocytes from Young Healthy Persons Carrying the ApoE4 Allele Overexpress Stress-Related Proteins Involved in the Pathophysiology of Alzheimer’s Disease. *J. Alzheimer’s Dis.* **2012**, *33*, 77–83, doi:10.3233/jad-2012-120973.

17. Brugulat-Serrat, A.; Rojas, S.; Bargalló, N.; Conesa, G.; Minguillón, C.; Fauria, K.; Gramunt, N.; Molinuevo, J.L.; Gispert, J.D. Incidental findings on brain MRI of cognitively normal first-degree descendants of patients with Alzheimer’s disease: A cross-Sectional analysis from the ALFA (Alzheimer and Families) project. *BMJ Open* **2017**, *7*, doi:10.1136/bmjopen-2016-013215.

18. Nakamura, A.; Cuesta, P.; Kato, T.; Arahata, Y.; Iwata, K.; Yamagishi, M.; Kuratsubo, I.; Kato, K.; Bundo, M.; Diers, K.; et al. Early functional network alterations in asymptomatic elders at risk for Alzheimer’s disease. *Sci. Rep.* **2017**, *7*, 6517, doi:10.1038/s41598-017-06876-8.

19. Busche, M.A.; Eichhoff, G.; Adelsberger, H.; Abramowski, R.; Wiederhold, K.-H.; Haass, C.; Staufenbiel, M.; Konnerth, A.; Garaschuk, O. Clusters of Hyperactive Neurons Near Amyloid Plaques in a Mouse Model of Alzheimer’s Disease. *Science* **2008**, *321*, 1686–1689, doi:10.1126/science.1162844.

20. Bateman, R.J.; Xiong, C.; Benzinger, T.L.; Fagan, A.M.; Goate, A.M.; Fox, N.; Marcus, D.S.; Cairns, N.J.; Xie, X.; Blazy, T.M.; et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. *N. Engl. J. Med.* **2012**, *367*, 795–804, doi:10.1056/NEJMoa1202753.

21. Dubois, B.; Hampel, H.; Feldman, H.H.; Scheltens, P.; Aisen, P.; Andrieu, S.; Bakardjian, H.; Benali, H.; Bertram, L.; Blennow, K.; et al. Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria. *Alzheimer’s Dement.* **2016**, *12*, 292–323, doi:10.1016/j.jalz.2016.02.002.

22. Koronyo, Y.; Salumbides, B.C.; Black, K.L.; Koronyo-Hamaoui, M. Alzheimer’s Disease in the Retina: Imaging Retinal A Plaques for Early Diagnosis and Therapy Assessment. *Neurodegener. Dis.* **2012**, *10*, 285–293.

23. Alber, J.; Goldfarb, D.; Hernandez, K.; Cheng, D.; Cordeiro, F.; Stavern, G.P.; Van, Snyder, P.J.; Thompson, L.I.; Debuc, D.C.; Arthur, E.; et al. Developing retinal biomarkers for the earliest stages of Alzheimer’s disease: What we know, what we don’t, and how to move forward. *Alzheimer’s Dement.* **2020**, *16*, 229–243.

24. Cheng, D.L.; Thompson, L.; Snyder, P.J. A Potential Association Between Retinal Changes, Subjective Memory Impairment, and Anxiety in Older Adults at Risk for Alzheimer’s Disease: A 27-Month Pilot Study. *Front. Aging Neurosci.* **2019**, *11*, 288, doi:10.3389/fnagi.2019.00288.

25. Van De Kreeke, J.A.; Nguyen, H.; Haan, J.D.; Konijnenburg, E.; Tomassen, J.; Braber, A.D.; Kate, M.T.; Collij, L.; Yaqub, M.; Van Berckel, B.; et al. Retinal layer thickness in preclinical Alzheimer’s disease. *Acta Ophthalmol.* **2019**, *97*, 798–804, doi:10.1111/aos.14121.

26. Santos, C.Y.; Johnson, L.N.; Sinoff, S.E.; Festa, E.K.; Heindel, W.C.; Snyder, P.J. Change in retinal structural anatomy during the preclinical stage of Alzheimer’s disease. *Alzheimer’s Dement.* **2018**, *10*, 196–209, doi:10.1016/j.dadm.2018.01.003.

27. Shi, Z.; Cao, X.; Hu, J.; Jiang, L.; Mei, X.; Zheng, H.; Chen, Y.; Wang, M.; Cao, J.; Li, W.; et al. Retinal nerve fiber layer thickness is associated with hippocampus and lingual gyrus volumes in nondemented older adults. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* **2020**, *99*, 109824, doi:10.1016/j.pnpbp.2019.109824.

28. The Early Treatment Diabetic Retinopathy Study. Grading Diabetic Retinopathy from Stereoscopic Color Fundus Photographs—An Extension of the Modified Airlie House Classification: ETDRS Report Number 10. *Ophthalmology* **1991**, *98*, 786–806.

29. Golzan, M.; Goozsee, K.; Georgievsky, D.; Avolio, A.P.; Chatterjee, P.; Shen, K.; Gupta, V.K.; Chung, R.; Savage, G.; Orr, C.; et al. Retinal vascular and structural changes are associated with amyloid burden in the elderly: Ophthalmic biomarkers of preclinical Alzheimer’s disease. *Alzheimer’s Res. Ther.* **2017**, *9*, 13, doi:10.1186/s13195-017-0239-9.
30. Snyder, P.J.; Johnson, L.N.; Lim, Y.Y.; Santos, C.Y.; Alber, J.; Maruff, P.; Fernández, B. Nonvascular retinal imaging markers of preclinical Alzheimer’s disease. *Alzheimer’s Dement.* **2016**, *4*, 169–178, doi:10.1016/j.jnd.2016.09.001.

31. Haan, J.D.; Van De Kreeke, J.A.; Van Berckel, B.N.; Barkhof, F.; Teunissen, C.E.; Scheltens, P.; Verbraak, F.D.; Bouwman, F.H. Is retinal vasculature a biomarker in amyloid proven Alzheimer’s disease? *Alzheimer’s Dement.* **2019**, *11*, 383–391, doi:10.1016/j.jnd.2019.03.006.

32. Vegeto, E.; Villa, A.; Della, T.S.; Crippa, V.; Rusmini, P.; Cristofani, R.; Galbiati, M.; Maggi, A.; Poletti, A. The Role of Sex and Sex Hormones in Neurodegenerative Diseases. *Endocr. Rev.* **2019**, *41*, 273–319, doi:10.1210/endre/bnz005.

33. Seltzer, M.M.; Li, L.W. The dynamics of caregiving: Transitions during a three-year prospective study. *Gerontologist* **2000**, *40*, 165–178.

34. Jefferson, A.L.; Lambe, S.; Chaisson, C.; Palmisano, J.; Horvath, K.J.; Karlawish, J. Clinical Research Participation among Aging Adults Enrolled in an Alzheimer’s Disease Center Research Registry. *J. Alzheimer’s Dis.* **2011**, *23*, 443–452, doi:10.3233/JAD-2010-101536.

35. Frohman, E.M.; Dwyer, M.G.; Frohman, T.; Cox, J.L.; Saltar, A.; Greenberg, B.M.; Hussein, S.; Conger, A.; Calabresi, P.; Balcer, L.J.; et al. Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: A pilot study. *J. Neurol. Sci.* **2009**, *282*, 96–105, doi:10.1016/j.jns.2009.04.010.

36. Gao, L.; Liu, Y.; Li, X.; Bai, Q.; Liu, P. Abnormal retinal nerve fiber layer thickness and macula lutea in patients with mild cognitive impairment and Alzheimer’s disease. *Arch. Gerontol. Geriatr.* **2015**, *60*, 162–167, doi:10.1016/j.archger.2014.10.011.

37. Salobrar-García, E.; De Hoz, R.; Ramírez, A.I.; López-Cuenca, I.; Rojas, P.; Vazirani, R.; Amarante, C.; Yubero, R.; Gil, P.; Pinazo-Durán, M.D.; et al. Changes in visual function and retinal structure in the progression of Alzheimer’s disease. *PLoS ONE* **2019**, *14*, e0220535, doi:10.1371/journal.pone.0220535.

38. Salobrar-García, E.; De Hoz, R.; Rojas, B.; Ramírez, A.I.; Salazar, J.J.; Yubero, R.; Gil, P.; Triviño, A.; Ramírez, J.M. Ophthalmologic Psychophysical Tests Support OCT Findings in Mild Alzheimer’s Disease. *J. Ophthalmol.* **2015**, *2015*, 1–10, doi:10.1155/2015/736949.

39. Shi, Z.; Zhu, Y.; Wang, M.; Wu, Y.; Cao, J.; Li, C.; Xie, Z.; Shen, Y. The Utilization of Retinal Nerve Fiber Layer Thickness to Predict Cognitive Deterioration. *J. Alzheimer’s Dis.* **2015**, *49*, 399–405, doi:10.3233/JAD-150438.

40. Shi, Z.; Wu, Y.; Wang, M.; Cao, J.; Feng, W.; Cheng, Y.; Li, C.; Shen, Y. Greater Attenuation of Retinal Nerve Fiber Layer Thickness in Alzheimer’s Disease Patients. *J. Alzheimer’s Dis.* **2014**, *40*, 277–283, doi:10.3233/JAD-131898.

41. Cunha, L.P.; Lopes, L.C.; Costa-Cunha, L.V.F.; Costa, C.F.; Pires, L.A.; Almeida, A.L.M.; Monteiro, M.L.R. Macular Thickness Measurements with Frequency Domain-OCT for Quantification of Retinal Neural Loss and its Correlation with Cognitive Impairment in Alzheimer’s Disease. *PLoS ONE* **2016**, *11*, e0153830, doi:10.1371/journal.pone.0153830.

42. Salobrar-García, E.; Rojas, B.; Ramírez, A.I.; De Hoz, R.; Salazar, J.J.; Yubero, R.; Gil, P.; Triviño, A.; Ramírez, J.M. Macular Thickness as a Potential Biomarker of Mild Alzheimer’s Disease. *Ophthalmology* **2014**, *121*, 1149–1151.e3, doi:10.1016/j.ophtha.2013.12.023.

43. Yap, T.E.; Balendra, S.I.; Almote, M.T.; Cordeiro, M.F. Retinal correlates of neurological disorders. *Ther. Adv. Chronic Dis.* **2019**, *10*, doi:10.1177/2040622319882805.

44. Acsaso, F.J.; Cruz, N.; Modrego, P.J.; Lopez-Anton, R.; Santabárbara, J.; Pascual, L.F.; Lobo, A.; Cristóbal, J.A. Retinal alterations in mild cognitive impairment and Alzheimer’s disease: An optical coherence tomography study. *J. Neurol.* **2014**, *261*, 1522–1530, doi:10.1007/s00415-014-7374-z.

45. Knoll, B.; Simonetti, J.; Volpe, N.J.; Farsiu, S.; Ward, M.; Rademaker, A.; Weintraub, S.; Fawzi, A.A. Retinal nerve fiber layer thickness in amnestic mild cognitive impairment: Case-control study and meta-Analysis. *Alzheimer’s Dement.* **2016**, *4*, 85–93, doi:10.1016/j.jnd.2016.07.004.

46. Garcia-Martín, E.; Bambo, M.P.; Marques, M.L.; Satue, M.; Otin, S.; Larrosa, J.M.; Polo, V.; Pablo, L. Ganglion cell layer measurements correlate with disease severity in patients with Alzheimer’s disease. *Acta Ophthalmol.* **2016**, *94*, 454–, doi:10.1111/aos.12977.

47. Cheung, C.Y.; Ong, Y.T.; Hilal, S.; Ikram, M.K.; Low, S.; Venkatasubramanian, N.; Yap, P.; Seow, D.; Chen, C.L.H.; Wong, T.Y.; et al. Retinal Ganglion Cell Analysis Using High-Definition Optical Coherence
Tomography in Patients with Mild Cognitive Impairment and Alzheimer’s Disease. *J. Alzheimer’s Dis.* 2015, 45, 45–56, doi:10.3233/jad-141659.

48. Beach, T.G.; Kuo, Y.-M.; Spiegel, K.; Emmerling, M.R.; Sue, L.I.; Kokjohn, K.; Roher, A.E. The Cholinergic Deficit Coincides with Aβ Deposition at the Earliest Histopathologic Stages of Alzheimer Disease. *J. Neuropathol. Exp. Neurol.* 2000, 59, 308–313, doi:10.1093/jnen/59.4.308.

49. Potter, P.E.; Rauschkolb, P.K.; Pandya, Y.; Sue, L.I.; Sabbagh, M.N.; Walker, U.G.; Beach, T.G. Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer’s disease. *Acta Neuropathol.* 2011, 122, 49–60, doi:10.1007/s00401-011-0831-1.

50. Jáñez-Escalada, L.; Jáñez-García, L.; Salobrar-García, E.; Santos-Mayo, A.; De Hoz, R.; Yubero, R.; Gil, P.; Ramírez, J.M. Spatial analysis of thickness changes in ten retinal layers of Alzheimer’s disease patients based on optical coherence tomography. *Sci. Rep.* 2019, 9, 13000–13014, doi:10.1038/s41598-019-49353-0.

51. Salobrar-García, E.; Ramírez, J.M.; De Hoz, R.; Rojas, P.; Salazar, J.J.; Yubero, R.; Gil, P.; Triviño, A.; Ramírez, J.M. The Impact of the Eye in Dementia: The Eye and its Role in Diagnosis and Follow-Up. In *Update on Dementia*; InTechopen; London: 2016.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).